FocalTherics’ (FOCL) “Buy” Rating Reiterated at HC Wainwright

FocalTherics (NASDAQ:FOCL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

FocalTherics Stock Up 10.6%

NASDAQ FOCL traded up $0.46 on Tuesday, reaching $4.78. The company had a trading volume of 71,204 shares.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.